Immersive theater and dance production thrills audiences at Point Park's Playhouse
A unique, immersive theater and dance production at Point Park University combines STEM and art, focusing on the elements of fire, air, water and earth, and it's probably unlike any performance you've ever attended.
"Ascend" is a family-friendly production choreographed and directed by Keisha Lalama, managing and artistic director of the Pittsburgh Playhouse at Point Park. She says she wanted the show to feel youthful, which is why her sons, who are in their 20s, helped write it.
In the theater space at the Pittsburgh Playhouse in Downtown Pittsburgh, the dancers perform around and among the audience, who is in the center.
"It's immersive but not invasive. I'm one of those people who doesn't want someone in my face. This is one of those experiences where you can participate or kind of sit back and observe," Lalama said.
The show has a corresponding educational component that many schools and youth community groups participated in before attending the show, including science experiments involving the different elements.
A field trip of high school students from Upper Saint Clair were inspired to move and dance with the performers.
"I'm still riding the high from it. That was awesome," junior Logan Campbell said.
"I'm a dancer, and it connected a lot of stuff for me. I loved it," said freshman Adriana Daniele.
"That was one of the coolest shows I've ever been to. I'm a theater nerd, and getting to do an interactive show was amazing," sophomore Cameron Calabrese said.
"Ascend" is family friendly and there is seating available for those who need it. The show is open to the public and runs through May 16.
And for more things to do with kids and families, check out kidsburgh.org.
KDKA is proud to partner with kidsburgh.org.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
39 minutes ago
- CBS News
Kilauea Volcano on Hawaii erupts for 25th time since December, spewing lava 330 feet high: "Here we go again!"
One of the world's most active volcanoes, Kilauea on Hawaii's Big Island, began spewing lava from the north vent Wednesday, the latest event in an ongoing eruption that began almost six months ago. Lava fountains reached heights of more than 330 feet and feeding multiple lava streams. Scientists with the U.S. Geological Survey's Hawaiian Volcano Observatory said the fountains were likely to go higher. "Here we go again!" the observatory wrote on its Facebook page. This image from webcam footage provided by the United States Geological Survey (USGS) shows lava fountains shooting up high in the latest episode of an ongoing eruption of Kilauea volcano inside Hawaii Volcanoes National Park on Wednesday, June 11, 2025. United States Geological Survey via AP The latest event was preceded by gas-pistoning, in which gas accumulates at a lava column's top within a vent, on Tuesday. The observatory said this process causes the lava surface to rise or piston. "Eventually, gas escapes as splatter/lava is erupted, and lave drains back into the vent," the observatory wrote. These were occurring up to 10 times an hour, but increased in intensity until a small, sustained dome fountain began to feed flows to the crater floor a day later. The USGS has set up three Kīlauea summit livestream videos, which can be seen here. It is the 25th eruptive episode since the volcano on the southeastern part of the island began erupting Dec. 23. It has been pausing and resuming since. Most of the eruptive episodes have spewed lava for about a day or less, with pauses between them generally lasting a few days. The USGS warned that high levels of volcanic gas can have far-reaching effects downwind. Sulfur dioxide (SO2) reacts in the atmosphere to create the visible haze known as vog (volcanic smog), which may cause respiratory and other problems, the agency said. Additional hazards include Pele's hair (strands of volcanic glass often produced by lava fountaining activity) and other volcanic fragments that can fall on the ground within a few hundred yards of the eruptive vents, the USGS said.
Medscape
41 minutes ago
- Medscape
Speeding Up Vericiguat Target Dose in HFrEF Shown Safe
Ditching the standard two-step pathway to the target 10-mg dose of vericiguat in patients with heart failure with reduced ejection fraction (HFrEF) and instead employing a one-step protocol can be done safely and overcome the clinical inertia many of these patients encounter, the lead investigator of a prospective clinical trial of the one-step approach said. The 2022 American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines recommend starting patients with HFrEF on a 2.5-mg dose of vericiguat, a soluble guanylate cyclase activator, then stepping up to a 5-mg dose enroute to reaching a target of 10 mg. VELOCITY Study Results Stephen Greene, MD However, the VELOCITY study found nine of 10 patients safely tolerated starting on the 5-mg dose and skipping the recommended 2.5-mg step, Stephen Greene, MD, an advanced heart failure specialist at Duke Cardiology Clinic in Durham, North Carolina, reported at the Heart Failure Association of the European Society of Cardiology (HFA-ESC) 2025. The study was simultaneously published in the European Journal of Heart Failure . 'We know from real-world evidence studies that, in US practice, there are many patients who are initiated on 5-mg vericiguat already, but now we have, actually, clinical data to suggest that this 5-mg initiation dose does appear to be safe among our patients that haven't had recent hypotension,' Greene told Medscape Medical News. The VELOCITY results make the case for updating the clinical guidelines for vericiguat, he added. The rationale for the study was to determine if starting patients closer to the target dose would give them a better chance of getting to and staying on the 10-mg target dose, according to Greene. 'Simplifying this process is one of the best ways to improve implementation for all our guideline-directed medical therapies,' Greene said. VELOCITY was a single-arm, two-week-long prospective trial that enrolled 106 patients with heart failure with an ejection fraction < 45% who were well-treated with background guideline-directed medical therapies. The primary endpoint was tolerability of 5-mg vericiguat dose after 2 weeks. Overall, 93.4% of patients tolerated the dose, including 90.6% in the group with worsening heart failure and 96.2% whose condition remained stable. Fourteen patients (13.2%) had an adverse event associated with treatment. One, a case of facial angioedema, was severe but the rest were considered mild. Four patients (3.8%) discontinued treatment because of an adverse event. VELOCITY also compared outcomes of those starting on the 5-mg dose with outcomes in the VICTORIA trial, which started patients on the 2.5-mg dose. In VICTORIA, 97.2% of patients tolerated the 2.5-mg starting dose over 2 weeks. Among patients with worsening heart failure, again 97.2% of VICTORIA patients tolerated the 2.5-mg treatment well, compared with 90.6% taking the 5-mg starting dose in VELOCITY. Greene also noted that patients in VELOCITY had 'the exact same mean reduction' in systolic blood pressure as those in VICTORIA: Both up to 3.2 mm HG on average. In VICTORIA, the placebo group also experienced a reduction in systolic blood pressure, he said, and the difference between the treatment and placebo groups was 1-to-2 mm HG. Had VELOCITY been a placebo study, the 3.2 mm HG reduction observed with the 5 mg dose 'likely would've been even further attenuated,' Greene said. 'This goes with what we already know about vericiguat, in that it seems to have minimal to no effect on systolic blood pressure.' Starting patients with HFrEF on 5 mg of vericiguat can help overcome 'clinical inertia' and increase the likelihood they will get to the 10-mg target dose, Greene said. 'Many of our patients with HFrEF never achieve target doses of guideline-directed medical therapies, and despite clinic visit after clinic visit, medication changes are, unfortunately, relatively rare,' Greene said. 'We see minimal medication titration, even when our patients have robust blood pressure, even when they have normal kidney function, even when we're talking about our inexpensive generic medications, we don't see many medication changes.' Time for Change, or 'Unique Strategy'? Ankeet S. Bhatt, MD, MBA, ScM Calling for a rewrite of clinical guidelines for using vericiguat in patients with HFrEF based on the VELOCITY results might be premature, Ankeet S. Bhatt, MD, MBA, ScM, a cardiologist and intensivist at Kaiser Permanente San Francisco Medical Center, told Medscape Medical News. 'VELOCITY really tests a unique strategy, reducing one of the steps in the titration of vericiguat, which may, if the clinical efficacy is confirmed in dedicated trials, bolster the confidence around early implementation at a higher dose of this therapy, without the need for an intra-dose titration,' Bhatt said. Validating the VELOCITY findings in a clinical trial 'might improve both acceptance from clinicians and the clinical implications about implementation of the therapy,' he added. Pairing the randomized clinical trial evidence with larger-scale real-world evidence would provide stronger evidence, he said. 'It's possible that there might be late effects or add-on effects that might either promote tolerability or might have safety concerns that we couldn't see in the context of this trial,' Bhatt said. 'So this is an important area that sets the stage, and when it's confirmed in real-world evidence, then I think we can make a compelling case that this might be an important addition to the guidance we already have.' This study was funded by Bayer and Merck Sharp & Dohme. Greene reported financial relationships with Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Corcept, Corteria Pharmaceuticals, CSL Vifor, Cytokinetics, Idorsia, Lexicon, Lilly, Merck, Novartis, Novo Nordisk, Otsuka, Pfizer, Roche Diagnostics, Sanofi, scPharmaceuticals, Sumitomo, and Tricog Health. Bhatt reported consulting for Merck.
New York Times
an hour ago
- New York Times
Inside Pat McAfee's world: Adam Schefter's ban, solo GameDay dreams, possibly more live events
Pat McAfee's style is born from WWE DNA. McAfee is a character with traces of Stone Cold Steve Austin, The Rock and Roman Reigns — only real. He is outlandish, impulsive and lives in his own McAfeesphere. McAfee's unpredictable nature in writing his script is intoxicating for his audience. Like the best WWE stars, he can have his hand out to shake on an agreement and then quickly pull it away. That's Pat McAfee's music. Advertisement In recent weeks, McAfee has touted '#UpToSomethingSZN' on his social media feeds, which is the term he uses when he is thinking about new deals. While he is currently under contract with ESPN and WWE, the constraints of signed agreements have never stopped him. McAfee tends to get what he wants, which was exemplified by the right to swear on ESPN during his daily talk program, 'The Pat McAfee Show.' This privilege, a first in the network's long history, was part of McAfee's five-year, $85 million-plus licensing agreement with ESPN that he signed in the spring of 2023. McAfee has two years left on his College GameDay contract. Last year, he considered not returning before re-signing. He has mused with associates about starting his own, independent version of GameDay, according to sources briefed on discussions. This does not appear to be happening, at least not now. But he is mercurial and can make big decisions seemingly on whims. McAfee cares about his image. During a GameDay stop in Norman, Oklahoma, last fall, McAfee grew upset about being shown swinging and missing during a segment in which he faced a University of Oklahoma softball pitcher. McAfee, according to sources briefed on the incident, demanded to know the name of the GameDay staff member who put it on the air, but he was denied the information. He has essentially banned ESPN NFL insider Adam Schefter from his program since March. The usually omnipresent Schefter hasn't been on 'The Pat McAfee Show' since that month's free agent deadline. Sources said that the main issue stemmed from one incident. One afternoon, McAfee wanted Schefter on his program. Schefter was appearing on an ESPN2 free agency special and was unable to make it. Schefter, formerly a McAfee Show regular, has been banished ever since. (A McAfee sidekick, Ty Schmit, has remained a regular on Schefter's podcast). Advertisement Schefter's rival, NFL Network's Ian Rapoport, has been on McAfee's show instead. Prior to McAfee's program airing on ESPN, Rapoport had been a regular. ESPN NFL newcomer Peter Schrager also has appeared. 'Pat and his show are thriving on ESPN,' ESPN president of content Burke Magnus said in a statement. 'We are very pleased with the partnership. That said, in the nearly three years since Pat has brought his show to our platforms, we've continuously seen those out there that are seemingly obsessed with wanting to see Pat fail on ESPN. This rumor is just the latest example of that. Pat and his show continue to break the mold and reach new audiences, and we look forward to the continued success together.' Magnus did not answer any questions. McAfee did not return messages. ESPN declined further comment. Hours after The Athletic reached out about Schefter's banishment, an ESPN spokesperson said that Schefter will return to McAfee's show on Thursday for the first time in around three months. Besides the behind-the-scenes machinations, McAfee has also been in the middle of on-air headlines. He has discussed a false internet rumor about an unknown 18-year-old college student, which made national headlines, called a now-former top ESPN executive a 'rat' and allowed Aaron Rodgers to pontificate political and medical theories on the all-sports network. McAfee likes to pretend like he is some dumb jock, but he is smart and has quickly figured out the sports media business. He can do good and charitable TV, like his must-see kicking segments during GameDay, where he has given college students the chance to make a field goal for hundreds of thousands of dollars. He and Nick Saban, a yin-and-yang combo, have breathed new life into the iconic program. All in all, McAfee freelances, not guided by some traditional media playbook. He is gutsy, willing to jump from his WWE commentator seat and into the ring, and then make a bet-on-himself career turn. Advertisement In 2017, McAfee, then just 29 with knee issues, walked away from a $2.8 million salary as the punter for the Indianapolis Colts to join Barstool Sports. After several moves, his popularity led to a reported four-year, $120 million deal with FanDuel. Two years ago, he left that contract before its completion to sign his licensing deal with ESPN. ESPN values its connection with McAfee, who attracts a younger audience, according to ESPN's internal data. He and Stephen A. Smith are the network's most talked-about personalities. McAfee's association with ESPN is part of its strategy as it dives into the full direct-to-consumer game beginning this fall. ESPN will make its service available without a cable or any other type of bundled subscription. (Fans with cable or a similar subscription will see no change to their ESPN access.) In ESPN's first 30-second promotion for the new venture, McAfee joined Smith, Scott Van Pelt, Malika Andrews and Dick Vitale as the only current on-air personalities shown. As part of the fall launch of the direct-to-consumer service, a campaign that ESPN has marketed as 'Sports Forever,' ESPN has been trying to add more content to the enhanced ESPN app to make it a go-to for existing and future customers. It failed in luring Colin Cowherd from Fox Sports but succeeded with former ESPN personality Rich Eisen, taking his daily show from Roku. Both Cowherd's and Eisen's talk shows happen to be on at the same time as McAfee's noon-3 p.m. ET program. They would not have replaced McAfee from noon-2 p.m on ESPN's main channel, but they will be available via streaming, like McAfee's show. 'We will have responses, as well,' McAfee said on the air after the Eisen news was public. McAfee did not offer up any specifics. Adding to the time-slot counter-programming, Smith will have his own SiriusXM program from 1-3 p.m. ET that will be in direct competition with McAfee. ESPN has plenty of on-air contributors to go around, but there may be more scoreboard-keeping from McAfee, as there was with Schefter in March. Advertisement McAfee clearly values the guests he has — and part of his personality seems to crave the WWE-type conflict. He writes the script and, like the best dramas, it is always hard to know where it is going to go. We will offer a prediction of sorts: McAfee will likely look to do more live events. In April, he performed in front of a reported crowd of more than 12,500 fans in an arena in Pittsburgh, where he grew up. His guests included big names, like singer Jelly Roll, comedian Shane Gillis and wrestler Jey Uso, among others. Maybe McAfee sets his sights on New Year's Eve and tries to create his own franchise, like a modern day Dick Clark or a counter to Ryan Seacrest and Anderson Cooper as the ball drops. McAfee could use his WWE instincts to find new rivals. He likes to be the one counter-programming.
